Mesa Laboratories' New CEO Puts Execution First as Q1 Margins Improve and Debt Falls
Mesa Laboratories (NASDAQ: MLAB) opened its fiscal 2027 with a 1% revenue increase, stronger margins and another round of debt paydown, but the quarter was also an early test for a new leadership team. In his first earnings call as president and CEO, Siddhartha Kadia framed Mesa as a company with durable, regulation-embedded franchises and "fixable execution problems," and he made clear the near-term priority is fixing those problems rather than pursuing acquisitions.
Total first-quarter revenue was $60.1 million, up 1% from a year earlier. Organic revenue also rose 1%, while core organic growth, excluding a 60-basis-point currency benefit, was 0.4%, according to CFO John Sakys.
"Mesa is a set of durable, regulation-embedded franchises with real and growing earnings power that had fixable execution problems," Kadia said. He said the company's focus will be on execution, capital reallocation and debt reduction.
Gross profit rose to $39.0 million, or 64.9% of revenue, from 62.0% in the prior-year quarter. Sakys attributed the roughly 290-basis-point improvement to lower spending on third-party contracted labor and consultants, supply-chain efficiencies and favorable product mix, partly offset by lower volume in the Sterilization and Disinfection Control segment, or SDC.
Operating expenses declined 5.6% to $32.0 million, helped by lower stock-based compensation and cost controls. GAAP operating income increased 129% to $7.0 million. Adjusted operating income rose 16.5% to $15.0 million, or $2.61 per diluted share. Excluding a $382,000 legal settlement, adjusted operating income was $15.4 million, representing 25.6% of revenue, compared with 21.7% in the year-ago quarter.
GAAP net income was $2.8 million, or $0.49 per diluted share, down 40.3% from a year earlier. Sakys said the decline was driven by a non-operating swing related primarily to unrealized foreign-currency gains and losses on an intercompany loan, rather than operating performance.
Cash flow from operating activities totaled $14.7 million, an increase of $12.8 million year over year. The company ended the quarter with $30.7 million in cash and cash equivalents and repaid $8.7 million of debt, reducing net leverage to 1.85 times. Mesa is targeting net leverage of roughly 1.5 to 1.75 times by the end of fiscal 2027.
SDC, Mesa's largest business and 41% of quarterly revenue, generated $24.5 million in sales, down 3.6% organically. Kadia said the shortfall reflected delivery reliability and fulfillment timing rather than weakened demand. The company's past-due backlog increased by about $1 million from its fiscal year-end level. He acknowledged that a production push in the fourth quarter of fiscal 2026 had reduced backlog substantially, but said the improvements were episodic rather than embedded in standard operating processes.
"The problem is that we missed delivery dates on orders we already hold," Kadia said. "That is a reliability problem, a promise-keeping problem."
He said Mesa will maintain its internal quality release standards for products involving biological materials while working to reduce process variability and shorten cycle times. The company's senior vice president of operations has been assigned to focus on the issue.
Despite the quarterly decline, SDC revenue increased from $93.4 million in fiscal 2025 to $101.6 million in fiscal 2026. On a trailing 12-month basis, SDC revenue stood at just over $100 million, up about 5% from a year earlier.
Biopharmaceutical Development, or BPD, posted 5% organic revenue growth to $12.1 million, following an almost 30% drop in the preceding quarter. Kadia said the result benefited in part from easier comparisons and catch-up orders that had been deferred because of export-control processing, cautioning that the quarter did not represent a completed turnaround. Mesa has appointed a new general manager for BPD and is rebuilding the segment's sales processes, pipeline discipline and commercial coverage. Kadia said the work is expected to take the better part of a year to become fully established.
The company also reprioritized its R&D portfolio to accelerate the next-generation Gyrolab automated immunoassay platform, which is now expected to launch in fiscal 2028. Kadia said the company is not providing revenue expectations for the product at this stage, but expects BPD to grow for the full fiscal year.
Calibration Solutions revenue rose 7.6% organically to $13.3 million, supported by its recurring service-driven revenue base. Clinical Genomics revenue was essentially flat at $10.3 million. Revenue in China declined 7%, while the rest of the business grew 0.6%. Kadia said China continues to face structural market issues, though Mesa's revenue exposure there has declined significantly over the past two years and is now below $3.5 million.
Mesa did not provide fiscal 2027 guidance on the call. Kadia said the company plans to issue full-year guidance with its second-quarter results in November, alongside first-half results. He said first-quarter trends were consistent with Mesa's internal plan and that management intends to reinvest some operating leverage in faster-growing, higher-return businesses. While the company may consider small distributor buyouts or tuck-in acquisitions later in the fiscal year, Kadia said the immediate priority is improving the performance of existing businesses and allocating resources toward SDC, BPD and Calibration Solutions.
Mesa Laboratories, headquartered in Lakewood, Colorado, provides instrumentation products designed for critical process monitoring, testing and calibration. Its end markets include healthcare, pharmaceutical, food and beverage, energy and industrial sectors. The portfolio covers biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers for oil, gas and petrochemical applications.
The quarter offered an early signal of how Kadia intends to run the company: less emphasis on dealmaking and more on converting Mesa's existing franchises into reliable, growing businesses. The next two quarters will be a test of whether the SDC fulfillment fixes become durable, and whether BPD's recovery can extend beyond catch-up orders.